CAMBRIDGE, Mass.– Orbital Therapeutics, a biotechnology company developing a new generation of RNA medicines that reprogram the immune system in vivo, has appointed Adam Raff, M.D., Ph.D., as Senior Vice President, Clinical Development. In his new role, Dr. Raff will lead the company’s clinical and regulatory operations and join its executive leadership team as Orbital advances OTX-201, a potential best-in-class program for B cell-driven autoimmune diseases, toward clinical development in the first half of 2026.
“Adam brings exceptional depth of experience in translating innovative science into impactful therapeutics, with a proven track record of successfully leading clinical development programs from discovery through pivotal trials,” said Ron Philip, Chief Executive Officer of Orbital. “His expertise in immunology and inflammatory diseases, combined with his background as a practicing physician-scientist, makes him ideally suited to advance Orbital’s diverse RNA medicine portfolio. He joins at a pivotal time as we progress OTX-201 through IND-enabling studies.”
Dr. Raff said he was drawn to Orbital’s mission and scientific approach: “Orbital’s first-in-kind platform at the intersection of RNA technology, delivery methods, and AI-guided design has tremendous potential to address unmet medical needs across multiple therapeutic areas. I’m excited to join this talented team and help translate Orbital’s innovative science into life-changing therapies for patients.”
Dr. Raff brings more than a decade of clinical and drug development experience in immunology and inflammatory disorders. He most recently served as Vice President and Head of Clinical Development at Montai Therapeutics, advancing several programs from discovery to IND-enabling studies. He previously held senior leadership roles at EQRx (acquired by Revolution Medicines in 2023) and LEO Pharma. Dr. Raff earned his M.D. and Ph.D. in Systems Biology with a focus on immunology from the University of Southern California and completed his dermatology residency through the Harvard Combined Dermatology Residency Program.
